Skip to content

Acupuncture Lowering Blood Pressure for Secondary Prevention of Stroke

Acupuncture Lowering Blood Pressure for Secondary Prevention of Stroke: Study Protocol for a Multicenter, Pragmatic,Randomized Controlled, Assessor-blinded Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02967484
Enrollment
480
Registered
2016-11-18
Start date
2016-11-20
Completion date
2020-05-31
Last updated
2017-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Infarction

Keywords

Acupuncture, Hypertension, Second prevention of Stroke, Efficacy, RCT, Study protocol

Brief summary

This study evaluate the effects of acupuncture method on the recurrence of ischemic stroke patients.Half of participants will receive Huo Xue San Feng acupuncture combining 1 antihypertensive medication on the routine ischemic stroke treatments' basis. While the other half will receive 1 antihypertensive medication and basic treatments for ischemic stroke.

Detailed description

Under recuiting 480 patients come from 5 hospitals in China.Eligible patients will be randomly assigned into 2 groups: treatment group and control group. The treatment group will receive Huo Xue San Feng acupuncture combining 1 antihypertensive medication on the routine ischemic stroke treatments' basis. The control group will receive 1 antihypertensive medication and basic treatments for ischemic stroke. Huo Xue San Feng acupuncture will be given six sessions weekly for the first 6 weeks and three times weekly for the next 6 weeks. A 9-month follow-up will thereafter be conducted. Antihypertensive medications will be adjusted based on BP levels.

Interventions

DEVICEacupuncture

1. Huo Xue San Feng acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36). 2. Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40). 3. Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic. The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)

Sponsors

State Administration of Traditional Chinese Medicine of the People's Republic of China
CollaboratorOTHER_GOV
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients with the first time ischemic stroke * Patients meet the TCM diagnosis standard of Stroke * Patients meet the diagnosis standard of hypertension, taking only 1 type of antihypertensive drugs for at least 2 weeks before admission,corresponding to systolic pressure ranging from 140 to 160mmHg and Diastolic ranging from 90-100mmHg. * The course of Ischemic stroke ranging from 2 weeks to 6 weeks . * Men or Women Aged between 35 and 70 years old. * Patients who are willing to participate in our clinical trial agree to sign the informed consent form.

Exclusion criteria

* Patients who have been diagnosed with secondary hypertension. * Patients have taken beta blockers or diuretics or non dihydropyridine calcium channel blocker (NDHP-CCB)for a long time because of cardiovascular disease. * Patients who taking 1 type of antihypertensive drugs,blood pressure under 140/90mmHg. * Patients accompanied with other neurological disorders,such as epilepsy, peripheral nerve injury, * Patients accompanied with severe medical condition such as severe hematopoietic system disease, coagulation dysfunction and malignant tumor. * Patients accompanied with diabetic nephropathy,severe liver and renal insufficiency,severe cardiac or pulmonary dysfunction,severe arrhythmia. * Patients who have occured skin infections near the acupoint location. * Pregnant or breast-feeding women. * Patients who currently participate in another clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
The Effects of Acupuncture on Reccurence of Ischemic Stroke1 year after enrollmentThe effects of acupuncture on reccurence of ischemic stroke assessed by China's Guidelines of Diagnosis and Treatment of Acute Ischemic Stroke 2014 and China's Guidelines of Diagnosis and Treatment of Cerebral Hemorrhage 2014.

Secondary

MeasureTime frame
Daily Blood Pressure by Electronic Sphygmomanometer1 year after enrollment
Antihypertensive Drug Stop/Resumption/Increasing Rate1 year after enrollment
Nitric Oxide(NO)the first day、12 weeks,6 months after enrollment
Endothelin(ET)the first day、12 weeks,6 months after enrollment
The Cardiac Color Doppler Ultrasonographythe first day、12 weeks after enrollment
Carotid Color Ultrasonographythe first day、12 weeks after enrollment
Brain Color Doppler Ultrasonographythe first day、12 weeks after enrollment
Lower Extremity Color Ultrasonographythe first day、12 weeks after enrollment
24-hour ambulatory blood pressurethe first day、6 weeks、12 weeks after enrollment
Short Form 36-item Health Survey (SF-36)the first day、6 weeks、12 weeks after enrollment
National Institute of Health stroke scale (NIHSS),as well as Barthel Index (BI) scalethe first day、12 weeks after enrollment
Essen stroke risk score (ESRS)the first day、1 year after enrollment
All-caused Morality1 year after enrollment
Serum homocysteine(Hcy)the first day、12 weeks,6 months after enrollment
Soluble CD40L(sCD40L)the first day、12 weeks,6 months after enrollment
Copeptinthe first day、12 weeks,6 months after enrollment
TCM syndrome scorethe first day、6 weeks、12 weeks after enrollment

Countries

China

Contacts

Primary Contactyuzheng Du
drduyuzheng11@163.com13702088266

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026